Aprocitentan Reduces Resistant Hypertension in CKD

The findings provide support for potentially using aprocitentan in patients with BP that remains elevated despite treatment with three established antihypertensive drug classes and with stage 3 CKD.

Related Keywords

Philadelphia ,Pennsylvania ,United States ,American ,Nishigandha Pradhan ,George Bakris ,Hypertension Center ,University Of Chicago ,American Society Of Nephrology ,University Hospitals In Cleveland ,Drug Administration ,Kidney Week ,American Society ,Comprehensive Hypertension Center ,University Hospitals ,Chronic Renal Failure ,Hronic Kidney Failure ,Hronic Kidney Disease Ckd ,Chronic Kidney Disease ,Kd ,Hypertension ,Renal Failure ,Enal Insufficiency ,Idney Insufficiency ,Kidney Failure ,Heart Failure ,Resistant Hypertension ,Esistant Htn ,Myocardial Infarction ,Antihypertensive ,Heart ,Renal Disease ,Kidney Disease ,Kidney Disorder ,Renal Disorder ,Ephropathy ,Diuretics ,Bedema ,Fluid Retention ,Kidn ,